WILMINGTON, DE, USA I April 29, 2013 I Incyte Corporation (NASDAQ: INCY) announced today that it has earned a $25.0 million milestone payment from Novartis based on the formal initiation of a Phase II clinical trial evaluating c-MET inhibitor INC280 (formerly INCB28060) as monotherapy in patients with advanced hepatocellular carcinoma. The Phase II trial is being conducted by Novartis as part of a Collaboration and License Agreement, in which Novartis received worldwide exclusive development and commercialization rights to INC280, and certain back-up compounds in all indications. Incyte has the option to co-develop INC280, and to co-detail the compound in the United States.
About INC280
c-MET is a validated target with potential in multiple oncology indications. INC280 is a potent, orally available selective inhibitor of the c-MET receptor tyrosine kinase. In preclinical models, INC280 has demonstrated favorable pharmacologic activity, and the compound can be dosed safely to achieve high levels of c-MET inhibition that result in tumor regression.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs for oncology and inflammation. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
SOURCE: Incyte
Post Views: 93
WILMINGTON, DE, USA I April 29, 2013 I Incyte Corporation (NASDAQ: INCY) announced today that it has earned a $25.0 million milestone payment from Novartis based on the formal initiation of a Phase II clinical trial evaluating c-MET inhibitor INC280 (formerly INCB28060) as monotherapy in patients with advanced hepatocellular carcinoma. The Phase II trial is being conducted by Novartis as part of a Collaboration and License Agreement, in which Novartis received worldwide exclusive development and commercialization rights to INC280, and certain back-up compounds in all indications. Incyte has the option to co-develop INC280, and to co-detail the compound in the United States.
About INC280
c-MET is a validated target with potential in multiple oncology indications. INC280 is a potent, orally available selective inhibitor of the c-MET receptor tyrosine kinase. In preclinical models, INC280 has demonstrated favorable pharmacologic activity, and the compound can be dosed safely to achieve high levels of c-MET inhibition that result in tumor regression.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs for oncology and inflammation. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
SOURCE: Incyte
Post Views: 93
